Literature DB >> 10190531

Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.

R Rajaratnam1, D B Brieger, R Hawkins, S B Freedman.   

Abstract

After 2 weeks of nicorandil therapy, time to ischemia on stress testing was significantly less than on day 1 and not different from placebo. These data are consistent with attenuation of the anti-ischemic effects of this drug and suggest that the potassium channel-opening properties do not compensate for development of attenuation to the nitrate component of nicorandil.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10190531     DOI： 10.1016/s0002-9149(99)00025-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 3.  Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Eur Cardiol       Date:  2018-08

Review 4.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 5.  Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Authors:  Dene Simpson; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.

Authors:  Barbara K Kemp-Harper; Anida Velagic; Nazareno Paolocci; John D Horowitz; Rebecca H Ritchie
Journal:  Handb Exp Pharmacol       Date:  2021

Review 8.  The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region.

Authors:  Kevin Cheng; Khaldoon Alhumood; Fayez El Shaer; Ranil De Silva
Journal:  Adv Ther       Date:  2020-12-22       Impact factor: 3.845

9.  Comparison of antiangina therapies in patients with coronary heart disease in China: study protocol for a multicentre, retrospective, hospital system-based study.

Authors:  Ping Li; Juan Chen; Zheng Ke; Jing Han; Lan Shen; Ning Zhou
Journal:  BMJ Open       Date:  2021-02-05       Impact factor: 2.692
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.